Professor Peter Schmid
Vice President for Healthcare Outcomes Policy and
Oncology and Molecular Radiation Sciences
Barts Cancer Institute
Norway
Biography
Professor of Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, St Bartholomew's Hospital & Barts Cancer Institute, November 2013-present Foundation Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, BSUH NHS Trust, BSMS, 2010-2013 Clinical Director, Clinical Investigation and Research Unit, BSUH NHS Trust, BSMS, 2010-2013 Senior Clinical Lecturer and Consultant in Medical Oncology, Director Hammersmith Early Clinical Trials Unit, Imperial College London, 2005-2010 Research Lead, Breast Cancer & Phase 1 Programme, Charité University Hospital, Berlin, Germany, 2002-2005 Lead Oncologist for Breast Cancer Services at Multidisciplinary Breast Centre, Charité University Hospital, Berlin, Germany, 2001-2005 Director, Clinical Trials Unit, Department of Oncology & Haematology, Charité University Hospital, Berlin, Germany, 2000-2005
Research Interest
My research interests primarily focus on breast cancer, lung cancer and early drug development.
Publications
-
Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014 Jun 5;12(1):93. PMID: 24898705 Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013 Oct 1;15(5):R92. PMID: 24286369 Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P et al. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol. 2014 Feb;25(2):505-11. PMID: 24368401 Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C et al. A Phase I dose escalation study to determine the optimal biological dose of irosustat – an oral steroid sulfatase inhibitor – in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treatment 2013 (in press); PMID: 23797179
